PMV Pharmaceuticals Reports Third Quarter 2026 Financial Results and Corporate Highlights
Pivotal Phase 2 rezatapopt PYNNACLE data to be featured in late-breaking oral presentation at ENA 2026Announced closing of oversubscribed $50 million public offering of securitiesRezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027Cash, cash equivalents, and marketable securities of $108.5 million as of September 30, 2026 providing expected cash runway into first quarter of 2028 PRINCETON, N.J., Nov. 10, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported fina